| Literature DB >> 28159821 |
Shahar Lavi1,2, Asim Cheema3,4, Andrew Yadegari5,2, Zeev Israeli5,2, Yaniv Levi5,2, Sabrina Wall5, Mistre Alemayehu5, Yasir Parviz5,2, Bogdan-Dorian Murariu5, Terry McPherson5,2, Jaffer Syed5,2, Rodrigo Bagur5,2.
Abstract
BACKGROUND: Radial artery occlusion is a known complication following transradial cardiac catheterization. A shorter duration of postprocedural radial clamp time may reduce radial artery occlusion (RAO) but might be associated with incomplete hemostasis. METHODS ANDEntities:
Keywords: angiography; cardiac catheterization; percutaneous coronary intervention; vascular complications
Mesh:
Year: 2017 PMID: 28159821 PMCID: PMC5523781 DOI: 10.1161/JAHA.116.005029
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1PRACTICAL study flow diagram.
Baseline Clinical Characteristics
| 20 Minutes (n=283) | 60 Minutes (n=285) |
| |
|---|---|---|---|
| Female | 81 (28.6%) | 88 (30.9%) | 0.56 |
| Age, y | 64.7±12.0 | 63.8±10.1 | 0.33 |
| Weight, kg | 89.9±20.2 | 87.6±20.6 | 0.18 |
| BMI, kg/m2 | 32.2±18.2 | 30.4±8.96 | 0.13 |
| Hypertension | 208 (73.5%) | 208 (73.0%) | 0.89 |
| Dyslipidemia | 202 (71.4%) | 204 (71.6%) | 0.96 |
| Diabetes mellitus | 83 (29.3%) | 77 (27.0%) | 0.54 |
| Current smoker | 44 (15.5%) | 42 (14.7%) | 0.77 |
| Creatinine, μmol/L | 84.5±32.8 | 87.2±43.2 | 0.43 |
| Prior radial approach | 26 (9.2%) | 39 (13.7%) | 0.09 |
| Prior CVA | 9 (3.2%) | 12 (4.2%) | 0.52 |
| Prior myocardial infarction | 36 (12.7%) | 55 (19.3%) | 0.04 |
| Prior PCI | 46 (16.3%) | 54 (18.9%) | 0.40 |
| Prior CABG | 5 (1.8%) | 8 (2.8%) | 0.41 |
| CCS grade | |||
| 0 | 71 (25.1%) | 85 (29.8%) | 0.21 |
| 1 | 63 (22.3%) | 67 (23.5%) | 0.40 |
| 2 | 92 (32.5%) | 86 (30.2%) | 0.94 |
| 3 | 30 (10.6%) | 26 (9.1%) | 0.74 |
| 4 | 23 (8.1%) | 17 (6.0%) | 0.42 |
| NYHA class | |||
| I | 178 (62.9%) | 187 (65.6%) | 0.49 |
| II | 78 (27.6%) | 67 (23.5%) | 0.26 |
| III | 19 (6.7%) | 21 (7.4%) | 0.76 |
| IV | 0 | 2 (0.7%) | |
| Barbeau's type | |||
| A/B | 248 (87.6%) | 260 (91.2%) | 0.17 |
| C | 10 (3.5%) | 5 (1.8%) | 0.20 |
BMI indicates body mass index; CABG, coronary artery bypass grafting; CCS, Canadian Cardiovascular Society; CVA, cerebrovascular accident; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
Procedure Characteristics
| 20 Minutes (n=283) | 60 Minutes (n=285) |
| |
|---|---|---|---|
| Sheath size (French) | |||
| 5 | 92 (32.5%) | 99 (34.7%) | 0.60 |
| 6 | 191 (67.5%) | 186 (65.3%) | 0.57 |
| Left ventricle ejection fraction | |||
| ≤40% | 38 (13.4%) | 43 (15.1%) | 0.56 |
| 41–50% | 35 (12.4%) | 42 (14.7%) | 0.40 |
| ≥51% | 181 (64.0%) | 174 (61.1%) | 0.51 |
| PCI performed | 78 (27.6%) | 77 (27.0%) | 0.90 |
| Artery intervened | |||
| LAD/diagonal | 32 (11.3%) | 32 (11.2%) | 0.98 |
| Cx/OM/intermediate | 18 (6.4%) | 22 (7.7%) | 0.53 |
| RCA | 33 (11.7%) | 24 (8.4%) | 0.20 |
| Other (LM/graft) | 1 (0.4%) | 4 (1.4%) | 0.18 |
| Anticoagulants | |||
| Heparin | 282 (99.6%) | 284 (99.6%) | 1 |
| GP IIb/IIIa bolus | 14 (4.9%) | 11 (3.9%) | 0.53 |
| GP IIb/IIIa infusion | 9 (3.2%) | 11 (3.9%) | 0.66 |
| Antiplatelets | |||
| Clopidogrel | 117 (41.3%) | 123 (43.2%) | 0.66 |
| Ticagrelor/prasugrel | 25 (8.8%) | 25 (8.8%) | 0.98 |
| Aspirin | 261 (92.2%) | 256 (89.8%) | 0.32 |
Cx indicates circumflex; GP, glycoprotein; LAD, left anterior descending; LM, left main; OM, obtuse marginal; PCI, percutaneous coronary intervention; RCA, right coronary artery.
Study Outcomes
| 20 Minutes (n=283) | 60 Minutes (n=285) |
| |
|---|---|---|---|
| RAO (primary end point) | 14 (4.9%) | 8 (2.8%) | 0.19 |
| Hemostasis during full pressure | |||
| Hematoma <5 cm | 4 (1.4%) | 7 (2.5%) | 0.37 |
| Hematoma >5 cm | 1 (0.4%) | 4 (1.4%) | 0.37 |
| Any bleeding or hematoma | 10 (3.5%) | 19 (6.7%) | 0.09 |
| Hemostasis after release | |||
| Hematoma <5 cm | 19 (6.7%) | 7 (2.5%) | 0.015 |
| Hematoma >5 cm | 5 (1.8%) | 4 (1.4%) | 0.75 |
| Any bleeding or hematoma | 53 (18.7%) | 40 (14.0%) | 0.13 |
| Retightening required (at any time) | 58 (20.5%) | 35 (12.3%) | <0.01 |
RAO indicates radial artery occlusion.
Number of participants who have at least 1: ooze, hematoma, and/or bleeding.
Patient Satisfaction
| Patient Satisfaction | 20 Minutes (n=177) | 60 Minutes (n=175) |
|
|---|---|---|---|
| During procedure | |||
| Access site comfort | 4.44±0.87 | 4.42±1.04 | 0.82 |
| Overall satisfaction | 4.67±0.67 | 4.64±0.79 | 0.73 |
| Following procedure | |||
| Access site comfort | 4.42±0.92 | 4.33±1.09 | 0.42 |
| Overall satisfaction | 4.46 (±0.62) | 4.69±0.63 | 0.82 |
Scores on each item range from 1 (unsatisfied) to 5 (satisfied).
Study Outcomes According to Sheath Size
| 5 French (n=191) | 6 French (n=377) | |||||
|---|---|---|---|---|---|---|
| 20 Minutes (n=92) | 60 Minutes (n=99) |
| 20 Minutes (n=191) | 60 Minutes (n=186) |
| |
| RAO (primary end point) | 3 (3.3%) | 1 (1%) | 0.35 | 11 (5.7%) | 7 (3.8%) | 0.36 |
| Hemostasis during full pressure | ||||||
| Hematoma <5 cm | 0 | 4 (4%) | 0.12 | 4 (2.1%) | 3 (1.6%) | 1.00 |
| Hematoma >5 cm | 1 (1%) | 0 | 0.48 | 0 | 4 (2.1%) | 0.058 |
| Any bleeding or hematoma | 3 (3.2%) | 8 (8.1%) | 0.15 | 7 (3.7%) | 11 (5.9%) | 0.34 |
| Hemostasis after release | ||||||
| Hematoma <5 cm | 6 (6.5%) | 4 (4%) | 0.53 | 13 (6.8%) | 3 (1.6%) | 0.01 |
| Hematoma >5 cm | 3 (3.2%) | 2 (2%) | 0.67 | 2 (1%) | 2 (1%) | 1.00 |
| Any bleeding or hematoma | 17 (18.5%) | 12 (12.1%) | 0.23 | 36 (18.9%) | 28 (15%) | 0.33 |
| Retightening required (at any time) | 15 (16.3%) | 10 (10%) | 0.20 | 43 (22.5%) | 25 13.4%) | 0.02 |
RAO indicates radial artery occlusion.
Number of participants who have at least 1: ooze, hematoma, and/or bleeding.
Predictors of RAO
| Variables | RAO (n=22) | No RAO (n=546) |
|
|---|---|---|---|
| Female | 3 (13.6%) | 166 (30.4%) | 0.09 |
| Age, y | 63.7±11.0 | 64.3±11.1 | 0.70 |
| Weight, kg | 88.2±19.4 | 88.7±20.5 | 0.57 |
| BMI, kg/m2 | 31.0±6.2 | 31.4±14.6 | 0.73 |
| Hypertension | 15 (68.2%) | 401 (73.4%) | 0.59 |
| Dyslipidemia | 5 (22.7%) | 157 (28.8%) | 0.54 |
| Diabetes mellitus | 12 (57.1%) | 394 (72.3%) | 0.13 |
| Current smoker | 6 (27.3%) | 80 (14.8%) | 0.11 |
| Creatinine, μmol/L | 88.3±20.1 | 85.7±39.0 | 0.73 |
| Prior radial approach | 4 (18.2%) | 61 (11.2%) | 0.31 |
| Prior CVA | 0 (0%) | 21 (3.8%) | 0.35 |
| Prior myocardial infarction | 2 (9.1%) | 89 (16.3%) | 0.37 |
| Prior PCI | 5 (22.7%) | 95 (17.4%) | 0.52 |
| Prior CABG | 0 (0%) | 13 (2.4%) | 0.46 |
| Sheath size (French) | |||
| 5 | 4 (18.2%) | 187 (34.2%) | 0.12 |
| 6 | 18 (81.8%) | 359 (65.8%) | |
| PCI performed | 11 (50.0%) | 144 (26.4%) | 0.02 |
| Antithrombotic | |||
| Heparin | 22 (100%) | 546 (100%) | — |
| GP IIb/IIIa inhibitors bolus | 1 (4.5%) | 24 (4.4%) | 0.97 |
| GP IIb/IIIa inhibitors infusion | 0 (0%) | 20 (3.7%) | 0.36 |
| Retightening required (at any time) | 8 (36.4%) | 85 (15.6%) | 0.01 |
BMI indicates body mass index; CABG, coronary artery bypass grafting; CVA, cerebrovascular accident; GP, glycoprotein; PCI, percutaneous coronary intervention; RAO, radial artery occlusion.